Pfizer Licensing Deal with WARF Allows Firm to Develop hESC-based Therapies, Discovery Tools

The agreement is the Wisconsin Alumni Research Foundation's 35th licensing deal with its 27th corporate partner for its IP portfolio related to isolating and differentiating hESCs. Pfizer is also the largest company and only pure-play pharma that WARF has disclosed as a licensee.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.